The following sets forth information about our executive officers as of April 18, 2022.March 19, 2024.
Sean A. McCarthy, D. Phil. | | | Chief Executive Officer and Chairman of the Board | | | 5557
|
Amy Peterson, M.D. (1)
| | | President, Chief Operating Officer
| | | 55
|
Carlos CampoyMarcia P. Belvin Ph.D.
| | | Senior Vice President, Chief FinancialScientific Officer | | | 57 |
Lloyd A. Rowland
| | | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
| | | 65
|
Alison L. Hannah, M.D.
| | | Senior Vice President, Chief Medical Officer
| | | 60
|
Jeff Landau | | | Senior Vice President, Chief Business Officer, and Head of Strategy | | | 4446
|
Chris Ogden
| | | Vice President, Finance and Accounting
| | | 38
|
(1)
| Dr. Peterson was promoted to the position of President and Chief Operating Officer of the Company in February 2022. |
The following is biographical information as of April 18, 2022March 19, 2024 for our executive officers.
Sean A. McCarthy, D. Phil., Chief Executive Officer and Chairman of the Board
Dr. McCarthy’s biographical information is included above under ““Proposal No.1 ElectionMcCarthy joined CytomX in December 2010 as our Chief Business Officer and became a member of Directors”.”
Amy Peterson, M.D., our Board of directors, President and Chief OperatingExecutive Officer
in August 2011. In January 2019, Dr. PetersonMcCarthy became Chairman of our Board of directors and currently serves as Chief Executive Officer and Chairman of our Board. Dr. McCarthy has more than twenty five years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the Schering Plough DNAX Research Institute, Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. After Millennium, Dr. McCarthy joined CytomX in October 2019SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as executive vice president business development and chief development officer. She was appointedhelped drive a strategic reorientation of the company from a platform business model to the positionproduct-focused oncology company, leading to completion of President and Chief Operating Officer of CytomXan initial public offering in February 2022. Prior2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from August 2016April 2006 to May 2019, Dr. Peterson was chief medical officer of immuno-oncology at BeiGene Ltd.,December 2010, where she created and led a global oncology development organization with direct medical oversight and accountability of seven clinical assets in over thirty global trials in all phases of development in solid tumor indications. Prior to BeiGene, from August 2011 to July 2016, Dr. Peterson was vice president of clinical development at Medivation, where she was primarily responsible for the development of enzalutamide (XTANDI ® and talazoparib (TALZENNA ® ) in breast cancer. Previously, Dr. Peterson served as associate group medical director at Genentech from 2005 to 2011, where shehe was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy currently serves as a member of the developmentboard of early stage molecules targetingdirectors of OncoResponse, Inc.. Dr. McCarthy is an author on multiple major pathwayspeer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in oncology. Prior to joining Genentech, Dr. Peterson wasbiochemistry and pharmacology at King’s College, University of London; an InstructorMBA from the Rady School of Medicine in OncologyManagement at the University of Chicago,California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. We believe Dr. McCarthy is qualified to serve on our Board based on his management experience in the life sciences sector, including at CytomX, his deep knowledge of the industry, and his strategic and business development expertise.
Marcia P.Belvin Ph.D., Senior Vice President, Chief Scientific Officer
Dr. Belvin joined CytomX in April 2018 as our Vice President of Research Oncology and currently serves as our Senior Vice President and Chief Scientific Officer, a position she has held since April 2022. Dr. Belvin has also served as our Head of Research since April 2020. Prior to her time at CytomX, Dr. Belvin held roles of increasing responsibility at Genentech, a publicly-traded biopharmaceutical company, where, from 2004 to 2018, she led multiple preclinical pipeline teams and oversaw programs in cancer signaling, cancer metabolism, and cancer immunology. Dr. Belvin began her career at Exelixis, a publicly-traded biopharmaceutical company, where she conducted translational research in tumor immunology in conjunction withserved as Senior Scientist from 1999 to 2004 and managed teams responsible for preclinical pipeline discovery within the oncology and inflammation portfolios. Dr. Thomas F. Gajewski. She currently serves on the board of The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. Dr. PetersonBelvin received her B.A. degree from Wesleyan University.
Carlos Campoy, Senior Vice President, Chief Financial Officer
Mr. Campoy joined CytomX as its chief financial officer in March 2020. Mr. Campoy brings over 30 years of financial and leadership experience, the majority from publicly held companies within the healthcare and biopharmaceutical sectors. Prior to joining CytomX, Mr. Campoy held the position of chief financial officer at Alder BioPharmaceuticals, Inc., a public biopharmaceutical company acquired in October 2019 by Lundbeck A/S, from December 2018 to November 2019. During his time at Alder, Mr. Campoy led the finance organization and readied the company for commercial launch of its lead program, eptinezumab. Prior to Alder, Mr. Campoy was a partner at Think Forwards, a boutique financial consulting firm, from September 2017 to December 2018. Prior to his position at Think Forwards, Mr. Campoy held the role of vice president of finance at Allergan plc from July 2014 to November 2016. Prior to joining Allergan, Mr. Campoy held senior financial leadership positions at Eli Lilly and Company from 1996 to 2014, including most recently as chief financial officer of Eli Lilly Japan K.K. Mr. Campoy holds a Certified Management Accountant (CMA) designation. Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil.
Lloyd A. Rowland, Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
Mr. Rowland joined CytomX in May 2018 as senior vice president, general counsel, secretary and chief compliance officer. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and